Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.


home / news releases / BVXV - BiondVax gains on collaboration to develop nanosized COVID-19 antibody therapy

BVXV - BiondVax gains on collaboration to develop nanosized COVID-19 antibody therapy

BiondVax Pharmaceuticals Ltd.
Nano-cap BiondVax Pharmaceuticals (NASDAQ:BVXV) has more than doubled in the pre-market on above-average volume after announcing the signing of definitive agreements with two German institutes for the development and commercialization of COVID-19 nanosized antibodies. The agreements with Max Planck Society (MPG) and the University Medical Center Göttingen (UMG) are part of a broader partnership expected to be signed in Jan. 2022, the company announced. The lead NanoAb COVID-19 candidates in the program have a robust competitive advantage over the current treatments for the disease, BiondVax (BVXV) argues. The company cites their ability to bind the target at concentrations 100-times lower than those required by commercially available monoclonal antibody treatments for COVID-19. The company expects to advance preclinical studies for COVID-19 NanoAb in 2022, with data from early human clinical trials anticipated in 2023.

For further details see:

BiondVax gains on collaboration to develop nanosized COVID-19 antibody therapy
Stock Information
Company Name: BiondVax Pharmaceuticals Ltd.
Stock Symbol: BVXV
Market: NASDAQ
Menu
BVXV BVXV Quote BVXV Short BVXV News BVXV Articles BVXV Message Board
Get BVXV Alerts

News, Short Squeeze, Breakout and More Instantly...